How to Treat a Lego Metastatic Disease

The patients that were included in GI 018 and in Ruby were big volume patients for the most part. They're not the patients that had one or two lymph nodes. And I think that's the tricky part when you start thinking about who to apply this to. The P53 mutated populations, seems to benefit from anti-VEGF signal. You know, should Pembrolizumab be in the mix? One of our proposals here is carboplatompaclitaxal pembrolizumsia plus minus bevacizumav.